ResearchMoz

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

GBI Research
Published Date » 2013-10-31
No. Of Pages » N/A
   
 GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products.  
   
 GBI Research analysis shows that the APAC ophthalmology market...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early AMD
2.4.2 Intermediate AMD
2.4.3 Advanced AMD
2.5 Co-morbidities and Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms and Prescribing Habits
2.9.3 Non-pharmacological Care

3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (Roche)
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer
3.1.5 Visudyne (verteporfin injection) – Novartis AG
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy and Safety

4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates in the Pipeline
4.5.1 MC-1101 – MacuCLEAR, Inc.
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD
6.2.4 Alcon Enters into Collaboration with AstraZeneca
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma
6.3.4 Lpath Enters into Licensing Agreement with Pfizer
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed and Phase 0
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables


Table 1: Macular Degeneration Market, Classification of AMD
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019
Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019
Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD
Figure 2: Macular Degeneration Market, Types of Dry AMD
Figure 3: Macular Degeneration Market, Classification of AMD
Figure 4: Macular Degeneration Market, Amsler Grid Test
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019
Figure 6: Macular Degeneration Market, Photodynamic Therapy
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products
Figure 14: Macular Degeneration Market, Global, Pipeline, 2013
Figure 15: Macular Degeneration Market, Global, Pipeline, 2013
Figure 16: Macular Degeneration Market, Global, Pipeline, 2013
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019
Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013
Figure 28: GBI Research Market Forecasting Model

Upcoming Reports:

Greece: bovine animals leather market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the bovina animal leathers market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the bovina animal leathers market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Trauma Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
The physical injuries such as burns, dislocations, fractures, sprains and strains caused by any external source are termed as trauma. According to the CDC, trauma is defined as “an injury or wound to a living body caused by the application of external force or violence”. To treat this trauma various procedures are available and their use is determined by the severity of injury. Trauma devices are one of the key treatment methods for the same.  The trauma devices can be categorized in two segments namely external fixation devices and internal fixation devices....
Rapid Microbiology Tests Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Rapid microbiology tests expedite the determination of a microorganism causing a symptomatic infection and hence help in selection of a method for its elimination. Rapid diagnosis of an infection with accuracy enables patient for early commencement of therapy and implementation of appropriate infection control measures. Such tests also reduce redundancy of un-required diagnostic testing and treatment. Current rapid microbiology tests include various genomic testing methodologies such as nucleic acid hybridization, polymerase chain reaction (PCR) technologies or nucleic acid sequencing....

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
China to Invest in UKs Infrastructure Industry
Oct 28, 2014  
As per industry reports, it is expected that in the year 2015, the UK infrastructure will derive benefits from 105 billion pounds of Chinese money. This will involve a host of Chinese machinery suppliers, contractors, and materials producers. The UK government will be spending about half of 225 billion pounds on its own infrastructure. The investors from China will be investing...